Follow-up of effectiveness in patients with inflammatory bowel diseases treated by ustekinumab and vedolizumab

Follow-up of effectiveness in patients with inflammatory bowel diseases treated by ustekinumab and vedolizumab - UV follow-up study in IBD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039947

Enrollment

Registered

2020-05-11

Start date

2020-05-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis and Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Active IBD patients who will be treated with ustekinumab and vedolizumab

Exclusion criteria

Exclusion criteria: 1. Patients with severe infection 2. Patients with active tuberculosis 3. Patients who has allergy against ustekinumab and vedolizumab 4. Maternal patients and patients with breastfeeding 5. Patients who has malignancy and who has past history of malignancy 6. Patients who has ostomy 7. Patients determined to be inappropriate for this study

Design outcomes

Primary

Measure	Time frame
Persistence of ustekinumab and vedolizumab at week 56	—

Countries

Japan

Contacts

Public ContactShingo Kato

Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology

skato@saitama-med.ac.jp049-228-3564

Outcome results